Study finds 20% of high-dose Brilinta patients quit on side effects; Novo touts cost-effectiveness analysis on GLP-1 med Victoza;

> A new analysis of Brilinta study data showed that about one in five heart attack patients on the highest dose of the AstraZeneca ($AZN) drug stopped taking it because of side effects. Report

> Novo Nordisk ($NVO) touted a company-funded study showing that Victoza, its GLP-1 diabetes drug, is more cost-effective than rival drugs from Sanofi ($SNY) and AstraZeneca ($AZN). Report

> The National Health Service in England published new guidance backing the use of AbbVie's ($ABBV) Humira in children with severe refractory uveitis, an inflammatory condition affecting the eye. Report

> Boehringer Ingelheim teamed up with a handful of top U.S. research institutions to develop new treatments for inflammatory bowel diseases such as Crohn's. Release

> And Finally... Allergan ($AGN), which makes Juvéderm facial fillers and other cosmetic treatments, released a survey showing that three-fourths of respondents worry that other people will misinterpret their "resting" facial expressions. Report

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.